Skip to content
OpenCapital
Get started

Arvinas ARVN Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$89.8M+7.5%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$2.10—

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%—

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0×0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's share-based payment - unrecognized cost of nonvested awards?
Arvinas (ARVN) reported share-based payment - unrecognized cost of nonvested awards of $45.8M in Q1 2026.
How has Arvinas's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
Arvinas's share-based payment - unrecognized cost of nonvested awards decreased by 37.8% year-over-year, from $73.6M to $45.8M.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.